According to a Decision Resources report pharmaceutical and healthcare industry analysts predict that the Chinese hepatocellular carcinoma (HCC; the most prevalent type of primary liver cancer) market will quadruple between 2006 and 2011. The report also finds that the small-molecule tyrosine kinase inhibitors will dominate the Chinese HCC market through 2011 because of the superior efficacy and safety profiles of these agents.

The findings were a part of an emerging markets study entitled Liver Cancer in China. Both financial and medical specialists for Decision Resources forecast that the growth in this industry in China will be fueled by increasing access to medical care, increased sales of existing therapies, and the introduction of novel targeted agents

A prescription drug used for treating patients with advanced kidney cancer could slow the disease progression in liver cancer patients as well, scientists said Monday. Presenting the findings during the 43rd annual meeting of the American Society of Clinical Oncology, researchers suggested that the oral tablets containing Sorafenib could provide a potential solution for the treatment of patients with fatal liver caner.

Sorafenib is an active ingredient in Nexavar tablets, co-developed by Bayer Pharmaceuticals Corp. and Onyx Pharmaceuticals Inc., used to treat patients with advanced kidney cancer

The U.S. Food and Drug Administration (FDA) approves a new drug to treat kidney cancer.

The drug Nexavar, made by German drugmaker Bayer AG and Onyx Pharmaceuticals Inc., can help curb the size and number of tumors in the most common form of kidney cancer, but has yet to make an impact on the length of life of the patients

The U.S. Food and Drug Administration (FDA) approves a new drug to treat kidney cancer.

The drug Nexavar, made by German drugmaker Bayer AG and Onyx Pharmaceuticals Inc., can help curb the size and number of tumors in the most common form of kidney cancer, but has yet to make an impact on the length of life of the patients